A genetics‑guided drug, compound 6, targets CARD9 to subtly calm gut inflammation in Crohn’s disease, pointing to safer, longer‑lasting, precision treatments.

NImmune Biopharma ("NImmune"), a private late-stage precision inflammation and immunology ("I&I") biopharmaceutical company, today announced that Executive Chairman, President and CEO Dr. Josep ...

Researchers have discovered a new biological pathway that is a principal driver of inflammatory bowel disease (IBD) and related conditions, and which can be targeted using existing drugs. Researchers ...

Amorphical, a developer of nano-amorphous mineral-based pharmacologic agents, today announced that long-term data from its Phase 2 trial in moderate-to-severe Crohn's disease will be presented at the ...

BBPH, bear bile powder high dose; BBPL, bear bile powder low dose; DSS, dextran sulfate sodium; NC, normal control; 5-ASA, 5-Amino salicylic acid. Ulcerative colitis (UC) is a chronic autoimmune ...

This study is led by Professor Fachao Zhi's research team from Nanfang Hospital, Southern Medical University. This study utilizes Western diet-fed mice to determine the role that the Western Diet ...

Several major advances in Crohn's disease have marked 2025, including two new FDA-approved therapies, emerging biologics that target novel pathways, and the first global standards for managing ...

Enhanced image showing where genes are active in colon tissue, revealing neutrophils located close to pre-cancerous epithelial cells [Longman Lab] It is known that inflammatory bowel disease (IBD) ...

PALI-2108 may offer a solution for fibrostenotic Crohn’s disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments Carlsbad, CA, Nov. 21, 2024 (GLOBE NEWSWIRE ...

Researchers at the Francis Crick Institute, working with UCL and Imperial College London, have discovered a new biological pathway that is a principal driver of inflammatory bowel disease (IBD) and ...